E2 ModeratePreliminaryPEM unclearCross-SectionalPeer-reviewedReviewed
A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis.
Brenu, Ekua W, Broadley, Simon, Nguyen, Thao et al. · Journal of immunology research · 2016 · DOI
Quick Summary
This study looked at specific immune cells called CD8+ T cells in people with ME/CFS and compared them to people with multiple sclerosis and healthy controls. Researchers found that ME/CFS patients had lower levels of certain proteins on their CD8+ T cells that help these immune cells function properly. These findings suggest that ME/CFS may involve problems with how immune cells are working, similar to but different from what happens in multiple sclerosis.
Why It Matters
Understanding differences in CD8+ T cell function between ME/CFS and other conditions like MS may help explain the unique pathophysiology of ME/CFS and could eventually guide development of targeted immune therapies. This study provides early evidence that ME/CFS involves measurable immune dysfunction, supporting the biological basis of the condition and potentially helping to differentiate it from other diseases.
Observed Findings
- CD127 expression was significantly decreased on all CD8+ T cell subsets in ME/CFS patients compared to nonfatigued controls.
- PSGL-1 expression was significantly reduced on CD8+ T cells in ME/CFS patients compared to controls.
- MS patients showed increased expression of BTLA, CD127, and CD49/CD29 on CD8+ T cell subsets, a pattern distinct from ME/CFS patients.
- CD8+ T cells from ME/CFS and MS patients demonstrated different immune receptor expression profiles despite both being systemic conditions.
- The study included 23 ME/CFS patients, 11 untreated MS patients, and 30 healthy controls.
Inferred Conclusions
- ME/CFS and MS are associated with significant deficits in CD8+ T cell surface receptor and adhesion molecule expression, but the patterns differ between conditions.
- Reduced CD127 and PSGL-1 on CD8+ T cells may contribute to immune dysfunction in ME/CFS pathogenesis.
- The distinct CD8+ T cell profiles between ME/CFS and MS suggest different underlying immune mechanisms despite some phenotypic similarities.
Remaining Questions
- What functional consequences do these CD8+ T cell abnormalities have for immune responses in ME/CFS patients?
- Do these immune markers correlate with ME/CFS symptom severity or disease duration?
What This Study Does Not Prove
This small preliminary study does not prove that CD8+ T cell abnormalities cause ME/CFS, only that they are associated with it. It cannot explain why these immune changes occur or what role they play in ME/CFS symptoms. The findings require confirmation in larger, well-powered studies before clinical significance can be established.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1155/2016/9064529
- PMID
- 26881265
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.